FDA-cleared profile

CT Cardiomegaly

Innolitics, LLC · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Automatically calculate linear and area-based cardiothoracic ratio from a CT study containing the heart to support clinician assessment of possible cardiomegaly; not for standalone clinical decision-making or diagnosis.

Clinical role
Automated heart and chest segmentation and CTR measurement; can run standalone or as part of another medical device, with clinician review of the summary report and all available information.
Images and patients
CT/CTA · Heart and thoracic cavity (cardiothoracic ratio)
Key limitation
Keep in mind: Results are not intended as the primary input for clinical decision-making or diagnosis and do not replace clinical assessment. The indication is limited to adults and transitional adolescents aged 18-21 treated as adults and to CT studies containing the heart; the FDA packet does not establish DICOM/PACS output or a clinical-disease detection claim.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Automatically calculate linear and area-based cardiothoracic ratio from a CT study containing the heart to support clinician assessment of possible cardiomegaly; not for standalone clinical decision-making or diagnosis.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart and thoracic cavity (cardiothoracic ratio) Input: A CT image study containing the heart; the software selects an axial slice containing the heart if present. The labeled population is adults and transitional adolescents aged 18-21 treated as adults.
  • Who uses it?Intended users: Physicians or other licensed practitioners in clinics, hospitals, healthcare facilities, residential care facilities, and long-term care services.
  • What does the software produce?Output: PDF and JSON summary reports containing linear-based CTR, area-based CTR or Heart to Chest Area Ratio, heart-area and inner-chest-area segmentations, patient information, and user-specified reference values.
  • What is its most important limitation?Key limitation: Results are not intended as the primary input for clinical decision-making or diagnosis and do not replace clinical assessment. The indication is limited to adults and transitional adolescents aged 18-21 treated as adults and to CT studies containing the heart; the FDA packet does not establish DICOM/PACS output or a clinical-disease detection claim.

Clinical takeaway. Clinical role: Automatically calculate linear and area-based cardiothoracic ratio from a CT study containing the heart to support clinician assessment of possible cardiomegaly; not for standalone clinical decision-making or diagnosis.

Evidence takeaway. Evidence from the reviewed source record: FDA K232613 reports technical performance against measurements from three board-certified radiologists. The testing set contained 275 unique patients from sites across 12 US states, aged 18-96 years, with varied scanners, protocols, contrast status, and CT types. Mean absolute difference was 0.009 for both CTR endpoints; 95% limits of agreement were [-0.033, 0.035] for CTR and [-0.028, 0.035] for Heart to Chest Area Ratio. Key-slice-position mean difference was 0.46 mm, and heart segmentation Dice was 0.95 (95% CI 0.950-0.956).

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatically calculate linear and area-based cardiothoracic ratio from a CT study containing the heart to support clinician assessment of possible cardiomegaly; not for standalone clinical decision-making or diagnosis.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Automated heart and chest segmentation and CTR measurement; can run standalone or as part of another medical device, with clinician review of the summary report and all available information.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
A CT image study containing the heart; the software selects an axial slice containing the heart if present. The labeled population is adults and transitional adolescents aged 18-21 treated as adults.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
PDF and JSON summary reports containing linear-based CTR, area-based CTR or Heart to Chest Area Ratio, heart-area and inner-chest-area segmentations, patient information, and user-specified reference values.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Clinics, hospitals, healthcare facilities, residential care facilities, and long-term care services.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Physicians or other licensed practitioners in clinics, hospitals, healthcare facilities, residential care facilities, and long-term care services.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Results are not intended as the primary input for clinical decision-making or diagnosis and do not replace clinical assessment. The indication is limited to adults and transitional adolescents aged 18-21 treated as adults and to CT studies containing the heart; the FDA packet does not establish DICOM/PACS output or a clinical-disease detection claim.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K232613 reports technical performance against measurements from three board-certified radiologists. The testing set contained 275 unique patients from sites across 12 US states, aged 18-96 years, with varied scanners, protocols, contrast status, and CT types. Mean absolute difference was 0.009 for both CTR endpoints; 95% limits of agreement were [-0.033, 0.035] for CTR and [-0.028, 0.035] for Heart to Chest Area Ratio. Key-slice-position mean difference was 0.46 mm, and heart segmentation Dice was 0.95 (95% CI 0.950-0.956).
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K232613 reports technical performance against measurements from three board-certified radiologists. The testing set contained 275 unique patients from sites across 12 US states, aged 18-96 years, with varied scanners, protocols, contrast status, and CT types. Mean absolute difference was 0.009 for both CTR endpoints; 95% limits of agreement were [-0.033, 0.035] for CTR and [-0.028, 0.035] for Heart to Chest Area Ratio. Key-slice-position mean difference was 0.46 mm, and heart segmentation Dice was 0.95 (95% CI 0.950-0.956).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

CT Cardiomegaly regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K232613
  • Samplen=275
  • IndependenceIndependence not established

K232613

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232613. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: A CT image study containing the heart; the software selects an axial slice containing the heart if present. The labeled population is adults and transitional adolescents aged 18-21 treated as adults.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K232613: CT Cardiomegaly

  2. Routing

    Source context, not route validation: Command-line software that may run standalone or as part of another medical device and writes PDF and JSON reports. The FDA packet does not establish a PACS, DICOM, RIS, EHR, or other specific external interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K232613: CT Cardiomegaly

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: PDF and JSON summary reports containing linear-based CTR, area-based CTR or Heart to Chest Area Ratio, heart-area and inner-chest-area segmentations, patient information, and user-specified reference values.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K232613: CT Cardiomegaly

  5. Viewer/worklist/report

    Unresolved route: PDF and JSON summary reports containing linear-based CTR, area-based CTR or Heart to Chest Area Ratio, heart-area and inner-chest-area segmentations, patient information, and user-specified reference values.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K232613: CT Cardiomegaly

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Command-line software that may run standalone or as part of another medical device and writes PDF and JSON reports. The FDA packet does not establish a PACS, DICOM, RIS, EHR, or other specific external interface.
  • Exact FDA submission
  • Checked 2026-09-08

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for CT Cardiomegaly; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K232613
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Heart and thoracic cavity (cardiothoracic ratio)
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-02-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K232613 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K232613: CT Cardiomegaly

    U.S. Food and Drug Administration - Published 2024-02-28 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CT Cardiomegaly model card (K232613)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K232613

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K232613 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253786

syngo.CT Coronary Cockpit

Siemens Medical Solutions USA, Inc.

Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2026-06-25
FDA-cleared K260324

Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

Canon Medical Informatics, Inc.

Authorized purpose: Assist assessment and pre-operative planning and post-operative evaluation of transcatheter aortic valve replacement procedures.

Modality
CT/CTA
Anatomy
Aortic valve/root, LVOT and ventricles, coronary ostia, cardiac structures, and iliac/femoral/abdominal aortic access vessels
Decision
2026-05-22
FDA-cleared K253596

Aquilion ONE (TSX-308A/TSX-306A) V2.0

Canon Medical Systems Corporation

Authorized purpose: Canon Aquilion ONE V2.0 acquires and processes whole-body CT volumes, including head, chest, abdomen, pelvis, cardiac, extremity, inner-ear, and multi-energy examinations with the labeled reconstruction functions.

Modality
CT/CTA
Anatomy
Whole body; head; chest; abdomen; pelvis; heart; extremities; and inner ear
Decision
2026-05-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history